
Aridis Pharmaceuticals ARDS
Quarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Book Value 2011-2026 | ARDS
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.2 M | -13.1 M | -8.68 M | 3.64 M | 26.3 M | 11.4 M | 13.8 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.3 M | -24.2 M | 1.31 M |
Quarterly Book Value Aridis Pharmaceuticals
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.8 M | -24.2 M | -35.8 M | -27.9 M | -20.4 M | -13.1 M | -4.16 M | -13.5 M | -8.56 M | -8.68 M | -8.68 M | -8.68 M | -8.68 M | 3.64 M | 3.64 M | 3.64 M | 3.64 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 11.4 M | 11.4 M | 11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.3 M | -35.8 M | -1.67 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Agenus
AGEN
|
314 M | $ 3.27 | -1.8 % | $ 1.17 M | ||
|
Agios Pharmaceuticals
AGIO
|
1.19 B | $ 29.33 | -2.98 % | $ 1.7 B | ||
|
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M | ||
|
Akebia Therapeutics
AKBA
|
32.6 M | $ 1.26 | -3.44 % | $ 324 M | ||
|
Akari Therapeutics, Plc
AKTX
|
22.2 M | $ 0.24 | 1.1 % | $ 5.73 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | ||
|
Aldeyra Therapeutics
ALDX
|
44.3 M | $ 5.49 | 0.52 % | $ 330 M | ||
|
AgeX Therapeutics
AGE
|
5.36 M | - | -10.17 % | $ 12.2 K | ||
|
Alector
ALEC
|
30.6 M | $ 2.26 | -7.2 % | $ 233 M | ||
|
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
Aligos Therapeutics
ALGS
|
92.1 M | $ 7.02 | -0.21 % | $ 451 M | ||
|
Alkermes plc
ALKS
|
1.82 B | $ 29.32 | -2.61 % | $ 4.83 B | ||
|
Allogene Therapeutics
ALLO
|
512 M | $ 2.57 | -7.73 % | $ 403 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 330.95 | -0.59 % | $ 43.4 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M | ||
|
Altimmune
ALT
|
124 M | $ 4.2 | -2.55 % | $ 298 M | ||
|
ALX Oncology Holdings
ALXO
|
114 M | $ 2.11 | 0.09 % | $ 110 M | ||
|
Amgen
AMGN
|
90.6 B | $ 387.85 | 0.03 % | $ 209 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 20.22 | -0.05 % | $ 945 M | ||
|
Amarin Corporation plc
AMRN
|
552 M | $ 13.62 | -1.3 % | $ 5.55 B | ||
|
AIM ImmunoTech
AIM
|
40.5 M | $ 0.92 | 5.25 % | $ 44.2 M | ||
|
AnaptysBio
ANAB
|
484 M | $ 54.61 | -0.8 % | $ 1.55 B | ||
|
Anika Therapeutics
ANIK
|
271 M | $ 14.44 | 0.53 % | $ 212 M | ||
|
ANI Pharmaceuticals
ANIP
|
429 M | $ 75.31 | 1.91 % | $ 1.45 B | ||
|
Annexon
ANNX
|
293 M | $ 5.38 | -3.93 % | $ 739 M | ||
|
Annovis Bio
ANVS
|
-7.75 M | $ 2.6 | -2.99 % | $ 23.5 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - | ||
|
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.53 | -2.05 % | $ 2.59 B | ||
|
Aptorum Group Limited
APM
|
11.8 M | $ 0.78 | -0.67 % | $ 4.25 M | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Aprea Therapeutics
APRE
|
22.7 M | $ 0.88 | -3.71 % | $ 3.18 M | ||
|
Aptevo Therapeutics
APVO
|
4.76 M | $ 7.28 | -0.55 % | $ 2.01 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
Aquestive Therapeutics
AQST
|
-60.2 M | $ 3.99 | -0.15 % | $ 346 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
241 M | $ 8.11 | -1.44 % | $ 219 M | ||
|
Ardelyx
ARDX
|
167 M | $ 6.32 | -3.54 % | $ 1.52 B | ||
|
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | ||
|
argenx SE
ARGX
|
5.5 B | $ 762.51 | -0.58 % | $ 25 B |